<DOC>
	<DOCNO>NCT02833142</DOCNO>
	<brief_summary>The primary objective study characterize pharmacokinetics ( PK ) BIIB033-B compare PK profile BIIB033-A healthy volunteer . Secondary objective : To assess safety tolerability BIIB033-A BIIB033-B ; To assess secondary PK parameter BIIB033-A BIIB033-B ; To assess immunogenicity BIIB033-A BIIB033-B .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Single Doses BIIB033 ( Opicinumab ) Produced 2 Manufacturing Processes</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<criteria>Key Ability understand purpose risk study provide sign date informed consent authorization use confidential health information accordance national local subject privacy regulation . Must body mass index 18 32 kg/m2 , inclusive . All male participant female participant childbearing potential must practice highly effective method contraception study willing able continue contraception 6 month dose study treatment . Male participant must unprotected sexual intercourse female pregnant breastfeeding study . Male participant must also willing refrain sperm donation least 6 month dose study treatment . Must good health determine Investigator ( designee ) , base medical history screening evaluation . Key History clinically significant cardiac , endocrine , gastrointestinal , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal major disease , determine Investigator . History ongoing malignant disease , include solid tumor hematologic malignancy ( exception basal cell carcinomas squamous cell carcinoma completely excise consider cure least 12 month prior Day 1 ) . Serious infection ( e.g. , pneumonia , septicemia ) determine Investigator , within 3 month prior Day 1 . Fever bacterial viral infection ( include upper respiratory tract infection ) within 2 week prior Day 1 . History severe allergic anaphylactic reaction , history allergic reaction opinion Investigator likely exacerbate component study treatment . Prior exposure BIIB033 . Female participant breastfeed pregnant Screening Day 1 , plan become pregnant study 6 month follow study drug administration . History , positive test result Screening , human immunodeficiency virus . History , positive test result Screening , hepatitis C virus antibody hepatitis B virus ( define positive hepatitis B surface antigen hepatitis B core antibody ) . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Healthy Volunteer</keyword>
	<keyword>opicinumab</keyword>
</DOC>